Donor cell leukemia arising from clonal hematopoiesis after bone marrow transplantation von Gondek, L P, Zheng, G, Ghiaur, G, DeZern, A E, Matsui, W, Yegnasubramanian, S, Lin, M-T, Levis, M, Eshleman, J R, Varadhan, R, Tucker, N, Jones, R, Gocke, C D

Volltext

Post-transplantation cyclophosphamide for GVHD prophylaxis in severe aplastic anemia von DeZern, A E, Luznik, L, Fuchs, E J, Jones, R J, Brodsky, R A

Volltext

MDS AND AUTO-IMMUNITY von Dezern, A.

Volltext

Comparison of clinical outcomes and prognostic utility of risk stratification tools in patients with therapy-related vs de novo myelodysplastic syndromes: a report on behalf of the... von Zeidan, A M, Al Ali, N, Barnard, J, Padron, E, Lancet, J E, Sekeres, M A, Steensma, D P, DeZern, A, Roboz, G, Jabbour, E, Garcia-Manero, G, List, A, Komrokji, R

Volltext

Comparison of risk stratification tools in predicting outcomes of patients with higher-risk myelodysplastic syndromes treated with azanucleosides von Zeidan, A M, Sekeres, M A, Garcia-Manero, G, Steensma, D P, Zell, K, Barnard, J, Ali, N A, Zimmerman, C, Roboz, G, DeZern, A, Nazha, A, Jabbour, E, Kantarjian, H, Gore, S D, Maciejewski, J P, List, A, Komrokji, R

Volltext

Long-term systemic lupus erythematosus disease control after allogeneic bone marrow transplantation von Gladstone, D E, Petri, M, Bolaños-Meade, J, Dezern, A E, Jones, R J, Fine, D, Brodsky, R A

Volltext

Glutathione Peroxidase Enzyme Activity in Aging von Espinoza, Sara E., Guo, Hongfei, Fedarko, Neal, DeZern, Amy, Fried, Linda P., Xue, Qian-Li, Leng, Sean, Beamer, Brock, Walston, Jeremy D.

Volltext

P572: VENETOCLAX AND HYPOMETHYLATING AGENT COMBINATIONS FOR THE TREATMENT OF ADVANCED MYELOPROLIFERATIVE NEOPLASMS AND ACUTE MYELOID LEUKEMIA WITH EXTRAMEDULLARY DISEASE von Sanber, K., Ye, K., Tsai, H.‐L., Newman, M., Ambinder, A., DeZern, A., Jain, T.

Volltext

PB1921: A RANDOMIZED, DOUBLE‐BLIND, PHASE 3 STUDY OF TAMIBAROTENE/AZACITIDINE VERSUS PLACEBO/AZACITIDINE IN NEWLY DIAGNOSED ADULT PATIENTS SELECTED FOR RARA‐POSITIVE HR‐MDS (SELECT... von DeZern, A., Marconi, G., Deeren, D., Diez Campelo, M., Lübbert, M., Krishnamurthy, P., Nagy, Z., Basak, G., Jonášová, A., Morozova, E., Geissler, K., Ofran, Y., Kelley, H., Volkert, A., Baker, K., Kang‐Fortner, Q., Hodgson, G., Madigan, C., Roth, D. A., Kelly, M., Fenaux, P.

Volltext

Evaluation of Salvage Induction Chemotherapy Regimens in Myelodysplastic Syndrome and Acute Myeloid Leukemia after Hypomethylating Agent Treatment Failure von Ball, B, Komrokji, R, Adès, L, Sekeres, M, DeZern, A, Pleyer, L, Vey, N, Almeida, A, Germing, U, Cluzeau, T, Platzbecker, U, Gore, S, Fenaux, P, Prebet, T

Volltext

A Phase I Trial of Ipilimumab (IPI) in Patients (PTS) with Myelodysplastic Syndromes (MDS) after Hypomethylating Agent (HMAS) Failure von Zeidan, A, Knaus, H, Robinson, T, Zeidner, J, Blackford, A, Duffield, A, Rizzieri, D, Frattini, M, Levy, M.Y, Schroeder, M, Ferguson, A, Sheldon, K, Dezern, A, Gojo, I, Gore, S, Streicher, H, Luznik, L, Smith, B.D

Volltext

320 RISK STRATIFICATION OF THERAPY-RELATED MYELODYSPLASTIC SYNDROMES (T-MDS): A REPORT ON BEHALF OF THE MDS CLINICAL RESEARCH CONSORTIUM von Komrokii, R, Zeidan, A, Al Ali, N, Padron, E, Lancet, J, Steensma, D, Dezern, A, Roboz, G, Jabbour, E, Sekeres, M, Garcia-Manero, G, List, A

Volltext

P787: SABATOLIMAB (MBG453) COMBINATION TREATMENT REGIMENS FOR PATIENTS WITH HIGHER‐RISK MYELODYSPLASTIC SYNDROMES: THE MYELODYSPLASTIC SYNDROMES STUDIES IN THE STIMULUS IMMUNO‐MYEL... von Zeidan, A. M., Al‐Kali, A., Borate, U., Cluzeau, T., DeZern, A. E., Esteve, J., Giagounidis, A., Kobata, K., Lyons, R., Platzbecker, U., Sallman, D. A., Santini, V., Sanz, G. F., Sekeres, M. A., Wei, A. H., Xiao, Z., Van Hoef, M., Nourry‐Boulot, C., Sadek, I., Ma, F., Iordan, A., Sabo, J., Garcia‐Manero, G.

Volltext

The efficacy of current prognostic models in predicting outcome of patients with myelodysplastic syndromes at the time of hypomethylating agent failure von Nazha, Aziz, Komrokji, Rami S, Garcia-Manero, Guillermo, Barnard, John, Roboz, Gail J, Steensma, David P, DeZern, Amy E, Zell, Katrina, Zimmerman, Cassie, Ali, Najla Al, Jabbour, Elias, Greenberg, Molly D, Kantarjian, Hagop M, Maciejewski, Jaroslaw P, List, Alan F, Sekeres, Mikkael A

Volltext

854P Final results of a phase II study of tipifarnib in chronic myelomonocytic leukemia (CMML) and other myelodysplastic/myeloproliferative neoplasms (MDS/MPN) von Patnaik, M.M., Sekeres, M.A., DeZern, A., Luger, S., Sproat, L., Bejar, R., Hobbs, G., Roboz, G.J., Leoni, M., Martell, B., Padron, E.

Volltext

Therapy-related myelodysplastic syndromes deserve specific diagnostic sub-classification and risk-stratification—an approach to classification of patients with t-MDS von Kuendgen, A., Nomdedeu, M., Tuechler, H., Garcia-Manero, G., Komrokji, R. S., Sekeres, M. A., Della Porta, M. G., Cazzola, M., DeZern, A. E., Roboz, G. J., Steensma, D. P., Van de Loosdrecht, A. A., Schlenk, R. F., Grau, J., Calvo, X., Blum, S., Pereira, A., Valent, P., Costa, D., Giagounidis, A., Xicoy, B., Döhner, H., Platzbecker, U., Pedro, C., Lübbert, M., Oiartzabal, I., Díez-Campelo, M., Cedena, M. T., Machherndl-Spandl, S., López-Pavía, M., Baldus, C. D., Martinez-de-Sola, M., Stauder, R., Merchan, B., List, A., Ganster, C., Schroeder, T., Voso, M. T., Pfeilstöcker, M., Sill, H., Hildebrandt, B., Esteve, J., Nomdedeu, B., Cobo, F., Haas, R., Sole, F., Germing, U., Greenberg, P. L., Haase, D., Sanz, G.

Volltext

Topic: AS08-Treatment/AS08f-Clinical trials – Phase II-III: SELECT-MDS-1 TRIAL IN PROGRESS: A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF TAMIBAROTENE/AZACITIDINE... von Dezern, A., Fenaux, P., Deeren, D., Campelo, M., Lübbert, M., Krishnamurthy, P., Nagy, Z., Basak, G., Jonasova, A., Geissler, K., Ofran, Y., Klimek, V., Volkert, A., Chisholm, J., Hu, B., Hodgson, G., Roth, D.A., Kelly, M., Marconi, G.

Volltext

Topic: AS03-Health Economics & Outcome Research/AS03a-Cost of care: ARE WE READY TO PERFORM NGS FOR ALL MDS PATIENTS ? von Santini, V., Bejar, R., Belli, C., Buckstein, R., Campelo, M., Dezern, A., Fontenay, M., Griffiths, E., Grille, S., Haferlach, T., Iastrebner, M., Kosmider, O., Magalhaes, S., Mittelman, M., Platzbecker, U., Wei, A., Zeidan, A.

Volltext

Consensus proposal for revised International Working Group 2023 response criteria for higher-risk myelodysplastic syndromes von Zeidan, Amer M., Platzbecker, Uwe, Bewersdorf, Jan Philipp, Stahl, Maximilian, Adès, Lionel, Borate, Uma, Bowen, David, Buckstein, Rena, Brunner, Andrew, Carraway, Hetty E., Daver, Naval, Díez-Campelo, Maria, de Witte, Theo, DeZern, Amy E., Efficace, Fabio, Garcia-Manero, Guillermo, Garcia, Jacqueline S., Germing, Ulrich, Giagounidis, Aristoteles, Griffiths, Elizabeth A., Hasserjian, Robert P., Hellström-Lindberg, Eva, Iastrebner, Marcelo, Komrokji, Rami, Kulasekararaj, Austin G., Malcovati, Luca, Miyazaki, Yasushi, Odenike, Olatoyosi, Santini, Valeria, Sanz, Guillermo, Scheinberg, Phillip, Stauder, Reinhard, van de Loosdrecht, Arjan A., Wei, Andrew H., Sekeres, Mikkael A., Fenaux, Pierre

Volltext

Topic: AS08-Treatment/AS08f-Clinical trials – Phase II-III: EFFICACY AND SAFETY OF ORAL DECITABINE/CEDAZURIDINE (ASTX727) IN THE CMML SUBPOPULATION FROM PHASE 2 AND ASCERTAIN PHASE... von Savona, M., Mccloskey, J., Griffiths, E., Yee, K., Zeidan, A., Al-Kali, A., Deeg, H.J., Patel, P., Sabloff, M., Keating, M.-M., Zhu, N., Gabrail, N., Fazal, S., Maly, J., Odenike, O., Kantarjian, H., Dezern, A., O’Connell, C., Roboz, G., Busque, L., Buckstein, R., Amin, H., Randhawa, J., Leber, B., Dao, K.-H., Sano, Y., Mirakhur, B., Keer, H., Garcia-Manero, G.

Volltext